BioCentury | Sep 28, 2018
Tools & Techniques

Deconstructing tox in immuno-oncology

The best route to improving preclinical toxicity in immunotherapies could lie in reverse translation, feeding clinical data back into the preclinical space to inform model development, rather than trying to guess a priori what the...
BioCentury | Sep 21, 2018
Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
BioCentury | Nov 14, 2013
Distillery Therapeutics

Indication: Inflammation

...Summary Licensing status Publication and contact information Inflammation Inflammation Hypoxia-inducible factor 1a subunit inhibitor (HIF1AN; FIH1...
...hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1) In vitro and mouse studies suggest inhibiting HIF1AN...
...suppressing IL-1b signaling. In cell culture, a pan-hydroxylase inhibitor or small interfering RNA knockdown of HIF1AN...
BioCentury | Apr 22, 2010
Distillery Therapeutics

Indication: Endocrine disease

...Hif1an-deficient mice, there was less diet-induced weight gain than there was in wild-type controls. The Hif1an-deficient...
BioCentury | Feb 21, 2007
Financial News

Bavarian Nordic raises $81.1 million

Bavarian Nordic (CSE:BAVA) raised DKK465 million ($81.1 million) in a rights issue through the sale of 1.3 million shares at DKK365, which is a 39% discount to BAVA's close of DKK600 on Monday, before the...
Items per page:
1 - 5 of 5